Tag: biosimilars vs generics
Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product’s price. This system encourages biosimilar entry but doesn’t strongly incentivize switching. Learn how billing works and why adoption remains low in the U.S.
Categories
Medications
Archives
Recent-posts
A Deep Dive Into ozmedsonline.com: How Online Pharmacies Are Changing Aussie Healthcare
Jul, 10 2025
Diacerein vs Alternatives: In‑Depth Comparison for Osteoarthritis
Oct, 25 2025
How to Talk to Your Doctor About New Drug Safety Alerts
Jan, 8 2026
Pregnancy and Sleep: How to Manage Apnea, Reflux, and Positioning for Better Rest
Mar, 18 2026
How the FDA Monitors Generic Drug Safety After Approval
Dec, 7 2025